This hypothesis is further supported by increased levels of both soluble vascular endothelial growth factor receptor 1 (sVEGFR1) and 2 (sVEGFR2) in the serum of T2D patients with PAD compared with nondiabetic PAD individuals (21) that could act as decoys to sequestrate VEGF-A (15). This evidence concerns the gene FLT1 and peripheral arterial disease.